13.67
전일 마감가:
$12.68
열려 있는:
$12.81
하루 거래량:
1.83M
Relative Volume:
1.70
시가총액:
$1.71B
수익:
$1.12B
순이익/손실:
$5.00M
주가수익비율:
1,367.00
EPS:
0.01
순현금흐름:
$-383.00M
1주 성능:
+13.54%
1개월 성능:
+14.11%
6개월 성능:
+20.33%
1년 성능:
-24.35%
Indivior Plc Stock (INDV) Company Profile
명칭
Indivior Plc
전화
804-379-1090
주소
234 BATH ROAD, SLOUGH, BERKSHIRE
INDV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
INDV
Indivior Plc
|
13.67 | 1.50B | 1.12B | 5.00M | -383.00M | 0.01 |
![]()
HLN
Haleon Plc Adr
|
10.93 | 50.62B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
168.59 | 73.64B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.92 | 4.12M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.57B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.52 | 20.82B | 16.54B | -1.64B | 749.00M | -1.45 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-28 | 개시 | Rodman & Renshaw | Buy |
2024-07-23 | 개시 | Piper Sandler | Overweight |
2024-04-03 | 개시 | Craig Hallum | Buy |
2023-07-13 | 개시 | Northland Capital | Outperform |
Indivior Plc 주식(INDV)의 최신 뉴스
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - GlobeNewswire Inc.
Indivior to delist from London Stock Exchange, maintain primary listing on Nasdaq - MSN
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Indivior PLC To Contact The Firm - ACCESS Newswire
Indivior’s exit comes as no surprise - The Times
Levi & Korsinsky Notifies Indivior PLC Investors of a Class Action Lawsuit and Upcoming DeadlineINDV - ACCESS Newswire
Opioid Use Disorder Market Projected to Witness Massive GrowthIndivior PLC, Alkermes plc - openPR.com
Trending tickers: The latest investor updates on Tesla, Palantir, Sanofi, Babcock and Indivior - Yahoo
Kalkine : Indivior’s Exit from London Exchange Impacts FTSE 100 Pharmaceutical Landscape - Kalkine Media
Indivior to delist from London Stock Exchangewill stay on Nasdaq - Insider Media Ltd
Drug maker Indivior joins London Stock Exchange exodus, 2 Jun 2025 11:00 - Shares Magazine
Kalkine : Indivior’s FTSE 100 Sector Shift: Delisting from London to Focus on Nasdaq Listing - Kalkine Media
Kalkine: Indivior Exits London as FTSE 100 Firm Focuses on Nasdaq - Kalkine Media
FTSE pharma giant joins London stock market exodus - The Telegraph
Indivior (INDV) Delists from London to Focus on U.S. Market - GuruFocus
Indivior brings curtain down on turbulent 11-year run in London - Proactive financial news
Indivior drops London listing to focus on U.S. market By Investing.com - Investing.com Nigeria
Indivior To Delist From LSE To Better Align With US Focused Business - Nasdaq
Indivior to cancel secondary listing in London - Sharecast.com
Indivior Plans to Cancel London Listing After Moving Primary to US - Bloomberg
Drug maker Indivior to abandon London stock market for the US - Yahoo
Indivior to Cancel London Stock Exchange Listing, Focuses on Nasdaq - TipRanks
Indivior to Cancel Secondary Listing on London Stock Exchange, Maintains Primary Nasdaq Listing | Indivior Stock News - paginasiete.bo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing - marketscreener.com
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | INDV Stock News - GuruFocus
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - Bluefield Daily Telegraph
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior PLC LawsuitINDV - ACCESS Newswire
Indivior Announces Patrick Barry as Chief Commercial Officer - The Malaysian Reserve
Indivior appoints Patrick Barry as Chief Commercial Officer By Investing.com - Investing.com South Africa
Indivior Announces Patrick Barry as Chief Commercial Officer | I - GuruFocus
Indivior appoints Patrick Barry as Chief Commercial Officer - Investing.com India
Indivior Announces Patrick Barry as Chief Commercial Officer | INDV Stock News - GuruFocus
Indivior PLC (INDV) Stock Analysis: A 30% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Investors in Indivior (LON:INDV) have seen solid returns of 156% over the past five years - Yahoo Finance
How To Trade (INDV) - news.stocktradersdaily.com
Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
Naloxone Market Projected To Witness Massive Growth, 2025-2032 - openPR.com
Court of Appeal upholds representative action strike out in Wirral Council v Indivior/Reckitt, but claimant applies for permission to appeal to Supreme Court - stewartslaw.com
Indivior PLC Aligns CEO Compensation with Long-Term Performance Goals - TipRanks
Indivior to Participate in Upcoming Investor Events - StreetInsider
Indivior to Participate in Upcoming Investor Events | INDV Stock News - GuruFocus
Indivior announces participation in investor conferences By Investing.com - Investing.com India
Indivior to Engage with Investors at Key Healthcare Conferences - TipRanks
Indivior to Participate in Upcoming Investor Events – Company Announcement - Financial Times
Drug Addiction Treatment Market Projected To Witness Massive - openPR.com
(INDV) Long Term Investment Analysis - news.stocktradersdaily.com
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Indivior advances GABA-B PAM program for substance use disorders through IND-enabling studies - BioWorld MedTech
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - Yahoo
Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your RightsINDV - ACCESS Newswire
Indivior Plc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):